AprilBio Co.,Ltd. (KOSDAQ:397030)
South Korea
· Delayed Price · Currency is KRW 64,300
+1,100 (1.74%)
At close: Apr 28, 2026
AprilBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 2,172 | 27,514 | - | 200 | 23,396 | Upgrade
|
| Revenue Growth (YoY) | -92.11% | - | - | -99.15% | - | Upgrade
|
| Cost of Revenue | 22.95 | 16.38 | 19.05 | 26.27 | 19.21 | Upgrade
|
| Gross Profit | 2,149 | 27,498 | -19.05 | 173.73 | 23,377 | Upgrade
|
| Selling, General & Admin | 4,608 | 6,654 | 4,582 | 4,054 | 4,490 | Upgrade
|
| Research & Development | 4,022 | 3,205 | 8,038 | 6,925 | 13,892 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.74 | 0.68 | 0.68 | 0.67 | 0.61 | Upgrade
|
| Other Operating Expenses | 93.81 | 63.2 | 74.54 | 75.96 | 61.16 | Upgrade
|
| Operating Expenses | 9,413 | 10,629 | 13,369 | 11,648 | 18,930 | Upgrade
|
| Operating Income | -7,264 | 16,869 | -13,388 | -11,474 | 4,446 | Upgrade
|
| Interest Expense | -618.94 | -1,420 | -930.54 | -29.78 | -2,114 | Upgrade
|
| Interest & Investment Income | 3,331 | 3,312 | 3,149 | 1,309 | 262.92 | Upgrade
|
| Currency Exchange Gain (Loss) | -783.33 | 2,121 | 93.21 | 1,086 | -161.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -3,734 | -754.03 | -3,028 | 149.97 | -55,147 | Upgrade
|
| EBT Excluding Unusual Items | -9,069 | 20,128 | -14,104 | -8,959 | -52,713 | Upgrade
|
| Gain (Loss) on Sale of Investments | -658.95 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0 | -25.87 | -0.01 | - | Upgrade
|
| Other Unusual Items | - | -122.8 | - | - | - | Upgrade
|
| Pretax Income | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 | Upgrade
|
| Net Income | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 | Upgrade
|
| Net Income to Common | -9,728 | 20,005 | -14,130 | -8,959 | -52,713 | Upgrade
|
| Shares Outstanding (Basic) | 23 | 22 | 21 | 20 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 22 | 21 | 20 | 8 | Upgrade
|
| Shares Change (YoY) | 3.49% | 2.60% | 9.17% | 134.61% | 139.04% | Upgrade
|
| EPS (Basic) | -429.00 | 913.00 | -661.64 | -458.00 | -6322.00 | Upgrade
|
| EPS (Diluted) | -429.00 | 913.00 | -661.64 | -458.00 | -6322.00 | Upgrade
|
| Free Cash Flow | -3,630 | 21,514 | -10,571 | -6,794 | 2,546 | Upgrade
|
| Free Cash Flow Per Share | -160.09 | 981.88 | -494.99 | -347.29 | 305.34 | Upgrade
|
| Gross Margin | 98.94% | 99.94% | - | 86.87% | 99.92% | Upgrade
|
| Operating Margin | -334.44% | 61.31% | - | -5737.15% | 19.00% | Upgrade
|
| Profit Margin | -447.88% | 72.71% | - | -4479.64% | -225.31% | Upgrade
|
| Free Cash Flow Margin | -167.14% | 78.19% | - | -3396.76% | 10.88% | Upgrade
|
| EBITDA | -6,574 | 17,575 | -12,714 | -10,881 | 4,934 | Upgrade
|
| EBITDA Margin | - | 63.88% | - | - | 21.09% | Upgrade
|
| D&A For EBITDA | 689.55 | 706.33 | 674.42 | 593.44 | 487.25 | Upgrade
|
| EBIT | -7,264 | 16,869 | -13,388 | -11,474 | 4,446 | Upgrade
|
| EBIT Margin | - | 61.31% | - | - | 19.00% | Upgrade
|
| Advertising Expenses | 1.53 | - | - | 14.33 | 3.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.